Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by Goldisgreaton Jul 24, 2017 9:18am
120 Views
Post# 26500578

RE:Summary

RE:SummaryDid i mist something where do you see a 3 years contract to me it is for 2017 the revenu.


DIAGNOS signs new contract valued at $ 4.16 Million USD (5.26 Million CAD) with the Government of Mexico at ISSSTE to screen and monitor 320,000 diabetics in 2017 further to a successful pilot program.



The response to the $5.3M contract by the market was muted and it initially left us perplexed.

However, looking back, there are a few factors that potentially account it:

 

1. The contract details - $5.3M for a 3 year contract. If you amortized the revenue for the period, it's roughly $1.75M per year. While it is welcome revenue, the contract fall short of making the company instantly profitable. For FY2016, ADK.V showed a $5M loss and reported a $32M debt.

Bullboard Posts